CD163 and breast neoplasm: Patients with breast tumors expressing CD163 in >25 % of cancer cells had significantly shorter survival time than patients with tumors expressing CD163 in <25 % of cancer cells, which was also reported on in an earlier study [11] (Fig. 6).